Lirentelimab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Lirentelimab (AK002) 是一种人源化 IgG1 单克隆抗体，靶向唾液酸结合的 Ig 样凝集素 8 (SIGLEC8)。Lirentelimab 诱导 IL-5 激活的嗜酸性粒细胞细胞凋亡并抑制 IL-5 介导的肥大细胞激活。Lirentelimab 可用于嗜酸性胃炎、十二指肠炎的研究。

Lirentelimab (AK002) is a humanized IgG1 monoclonal antibody that targets sialic acid-binding Ig-like lectin 8 (SIGLEC8). Lirentelimab induces cell apoptosis of IL-5-activated eosinophils and inhibits IgE-mediated mast cell activation. Lirentelimab can be used for the research of eosinophilic gastritis and duodenitis.

Apoptosis Analysis Cell Line:Eosinophils Concentration:10 μg/mL-1 pg/mL Incubation Time:30 min Result:Dose-dependently induced apoptosis of IL-5-activated (50 ng/mL) eosinophils.

Animal Model:Humanized mice (NSG-SGM3) engrafts with human thymus, liver, and HSC Dosage:100 μg Administration:Intravenous injection; 100 μg, once Result:Completely prevented passive systemic anaphylaxis (PSA) as shown by a lack of change in rectal temperature and symptom scores in mice.

——

Apoptosis

Apoptosis

Apoptosis

——

——

2283348-97-8

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years